Desire studies
PT-141 research: questionnaires and experiments
A medicine has to accomplish something worth the body’s trouble. The desire trials give that question a measured answer, with a rather modest scale.
PT-141 for women
The RECONNECT trials enrolled 1267 premenopausal women with HSDD and compared as-needed subcutaneous bremelanotide with placebo over 24 weeks. The participants had distressing low desire, the condition covered by the approval. Both trials met their coprimary endpoints: the main measurements of desire and distress.
The integrated FSFI-desire difference was +0.35 versus placebo. FSFI is the Female Sexual Function Index, a questionnaire; its desire domain provided one of those endpoints. The integrated difference on FSDS-DAO item 13 was -0.33. This item asks about distress over low desire. Both differences had P<.001.
I’m glad distress was measured. A change in how troubling low desire feels seems a more humane aim than treating sexual activity as a quota. At the same time, the small average differences leave plenty of room for disagreement about the practical value of treatment.

PT-141 follow-up findings
The 52-week open-label extension enrolled 684 women. Sexual-desire improvements were sustained and no new safety signals emerged. Participants and investigators knew the treatment being given, so this follow-up supplies a different kind of observation from the blinded placebo comparison.
I wince at “safe” as a summary of a report with so much nausea. A familiar burden can still be a serious burden to the person experiencing it, and it sits alongside the sustained desire result in the same report.
A 2025 conference abstract on arousal and orgasm reported positive effects in premenopausal women beyond the main desire measurements. Its status as a conference abstract limits how much detail is available. Until a fuller account appears, I’m cautious about giving those broader outcomes the weight of the pivotal trials.
Human imaging; animal experiments
A crossover brain-imaging study in 31 premenopausal women with HSDD found increased sexual desire for up to 24 hours and altered brain responses to erotic stimuli. This is useful evidence of central processing, alongside the larger clinical trials.
The animal experiments ask more specific biological questions. In female rats, PT-141 increased sexual solicitation without changing lordosis, pacing or general movement. In female Syrian hamsters, bremelanotide did not enhance sexual reward in a conditioned-place-preference test. The species and measured behaviours differ. These experiments help investigate the mechanism; the human benefit still has to be established in people.
PT-141 for men
Male use remains off-label. The early PT-141 pharmacology report described erectile responses in men alongside rat and nonhuman-primate work. A 2024 clinic conference abstract concerns off-label use in men with sexual dysfunction. These findings have a different population and a less developed evidence base than the approved female-HSDD use.
The developer’s June 2024 announcement of a Phase 2 combination study concerned bremelanotide with a PDE-5 inhibitor in men who did not respond to the inhibitor alone. That announcement records a development plan at that date. It supplies no peer-reviewed treatment result.